| 2026-08-14 | Press release | Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 |
| 2026-07-28 | Press release | Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development |
| 2026-06-29 | Press release | Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit |
| 2026-06-16 | Press release | Enveric Biosciences Announces Participation in 2026 BIO International Convention |
| 2026-06-09 | Press release | Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day |
| Press release | Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 |
| Press release | Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 |
| 2026-05-13 | Press release | Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders |
| 2026-05-05 | Press release | Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies [Benzinga] |
| 2026-04-21 | Press release | Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum |
| 2026-04-18 | Press release | Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model |
| 2026-04-17 | Press release | Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
| 2026-04-16 | Press release | Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
| 2026-03-31 | Press release | Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates |
| 2026-03-27 | Press release | Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 202 |
| 2026-03-18 | Press release | Enveric Biosciences Announces Registration of Five Trademarks |
| 2026-02-25 | Press release | Enveric Biosciences Announces Withdrawal of Petition Against Its Patent |
| 2026-02-19 | Press release | Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data |
| 2026-01-29 | Press release | Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option |
| 2026-01-28 | Press release | Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| 2026-01-28 | Press release | Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| 2025-12-12 | Press release | Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds |
| 2025-12-11 | Press release | Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds |
| 2025-12-09 | Press release | Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates |
| 2025-12-04 | Press release | Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innova |
| 2025-11-21 | Press release | Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates |
| 2025-10-22 | Press release | Enveric Biosciences Announces Reverse Stock Split |
| 2025-10-16 | Press release | Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance |
| 2025-10-15 | Press release | Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquire |
| 2025-10-14 | Press release | Enveric Biosciences to Explore Digital Asset Treasury Opportunities |
| 2025-09-18 | Press release | Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds |
| 2025-09-17 | Press release | Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neu |
| 2025-09-03 | Press release | Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference |
| 2025-09-02 | Press release | Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA |
| 2025-06-24 | Press release | Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 |
| 2025-06-16 | Press release | Enveric Biosciences Announces Participation in 2025 BIO International Convention |
| 2025-05-28 | Press release | Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 |
| 2025-05-20 | Press release | Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease |
| 2025-03-28 | Press release | Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 202 |
| 2025-03-17 | Press release | Enveric Biosciences Participating in BIO-Europe Spring® |